Employers should explore outcomes-based agreements with drug manufacturers, according to a column by David Burda, MSP-C editorial director and chief health care subject matter expert.
Burda says the contracts, which emphasize value, could help “turn the tide in the fight” against medications carrying exorbitant price tags.
“Value-based reimbursement is a thing in health care,” Burda writes. “It means payers like employers and health plans reimburse hospitals and doctors based on the outcomes of the care they provide.”
Burda writes outcomes-based deals have mostly been confined to providers, but “forward-looking employers and health plans” won’t cough up the money unless the specialty treatments work.
To read Burda’s full column on Twin Cities Business, click here.